Neuphoria (NEUP) Forward P/S Multiple

Neuphoria Therapeutics Inc. focuses on the therapy of anxiety disorders and Alzheimer's disease, which is why the GURU.Markets system displays this chart, where the forward P/S indicator shows a metric value of 11.50. Growth potential is driven by the low-cost synthesis of proprietary blockbuster drugs. Prospects are further bolstered by the development of innovative ion channel modulators to combat PTSD and social phobia.
Comprehensive metric breakdowns and analytics for Neuphoria Therapeutics (NEUP)

The forward P/S reflects the ratio of the current market value of Neuphoria Therapeutics Inc. (NEUP) to expected annual sales, allowing for an assessment of asset revaluation dynamics between reporting periods. By analyzing the forward P/S trend, an investor determines the extent of priced-in expectations, which is critical for a company with a compact staff of neurobiologists where business value depends not on personnel scale, but on the success of clinical trials.